<DOC>
	<DOC>NCT00886366</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.</brief_summary>
	<brief_title>Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients</brief_title>
	<detailed_description />
	<criteria>Part A,Healthy male subjects, aged between ≥20 and ≤40 years. Part B,Male T2DM patients, aged between ≥20 and ≤65 years. Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrollment Part A,Clin sign illness or clin relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the IP. Part A Clin sign abnormalities in clinical chemistry, haematology, or urinalysis results as judged by the investigator Part B, History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease. Any clinically significant abnormality identified on physical examination, laboratory tests or ECG, which in the judgment of the investigator would compromise the patient's safety or successful participation.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Type II Diabetes</keyword>
</DOC>